IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
September 30, 2024 08:00 ET
|
Ichnos Glenmark Innovation
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
June 26, 2024 07:00 ET
|
Lyell Immunopharma, Inc
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...
Theratechnologies présente des données précliniques au congrès 2024 de l’AACR qui met en évidence la polyvalence et la flexibilité de la plateforme technologique d’oncologie SORT1+(MC)
April 08, 2024 16:30 ET
|
Theratechnologies
Les nouveaux conjugués camptothécine-peptide sont bien tolérés et associés à une régression tumorale marquée dans les modèles de xénogreffe de cancer colorectal et de cancer du sein triple...
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
April 08, 2024 16:30 ET
|
Theratechnologies
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft modelsSORT1 gene silencing...
ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie
March 25, 2024 09:00 ET
|
ProLynx Inc.
SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial...
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
March 05, 2024 16:30 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market - AstraZeneca, Daiichi Sankyo, Pfizer, OncoSec, Merck, OncoPep, Roche
November 28, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market -...
Triple-Negative Breast Cancer Treatment Market Size to Surpass US$ 20 Billion by 2030
September 25, 2023 14:45 ET
|
Zion Market Research
NEW YORK, United States, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Triple-Negative Breast Cancer Treatment Market By Drug Type...
Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight
July 10, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 10, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight The prevalence of triple-negative breast...
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
May 02, 2023 08:15 ET
|
Qualigen Therapeutics, Inc.
Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...